VALBIOTIS
7.6.2021 17:42:05 CEST | Business Wire | Press release
Press release
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the appointment of Sébastien BESSY as Chief Operating Marketing and Business Officer.
As of June 8, 2021, Sébastien BESSY will be responsible for the global deployment and coordination of the international strategy related to Valbiotis’ marketing and commercial development in order to support the growth of the Company, and strengthen and develop strategic alliances.
Furthermore, Sébastien BESSY, as a member of the Strategic Direction Board and then of the Supervisory Board of Valbiotis since 2014, will become a member of the Board of Directors as of his appointment.
Sébastien PELTIER, CEO, Chairman of the Board of Directors, comments: "We are delighted to welcome Sébastien BESSY to the Valbiotis Board of Directors. He will drive the Company's ambition at a pivotal time as we prepare the market launch of our first four active substances in development. Sébastien BESSY has in-depth knowledge of the challenges of the healthcare sector with over 20 years of experience in Consumer Healthcare at international pharmaceutical groups. His highly strategic expertise in key markets is a crucial asset that will enable Valbiotis to accelerate its momentum in the future and to strengthen and develop alliances. With our multitarget active substances, we aim to transform the health experiences of millions of people around the world. The appointment of Sébastien BESSY is perfectly in tune with this objective, and the ability to establish our products thanks to high level market expertise will be a decisive asset in shaping Valbiotis' success."
Sébastien BESSY is an expert in the Consumer Healthcare sector, having held various marketing and innovation positions at major pharmaceutical companies over the past 20 years. He has unique international experience, both operational and strategic, in consumer marketing and product innovation, particularly in Europe, Asia including China, North America and Latin America.
During his last 6 years at Ipsen, Sébastien BESSY held the positions of Vice-President Global Marketing & Portfolio Strategy Consumer Healthcare and Vice-President Global Strategic Operations Consumer Healthcare. Prior to joining Ipsen, Sébastien BESSY previously held the positions of Managing Director Europe at Biofortis, a subsidiary of Mérieux Nutrisciences, Global Director of "Probiotic Platform" Innovation at Merck Consumer Healthcare, Global Strategic Marketing Director at Merck Consumer Healthcare and Global Marketing Manager at Reckitt Benckiser.
Sébastien BESSY is a graduate of ISC Paris and began his career at Sanofi Aventis.
Sébastien BESSY adds: ‘I am delighted to join Valbiotis at this time of accelerated development. Throughout my career, in different markets around the world, I have been committed to bringing more and more innovations to patients. I am very excited to join this dynamic company with a clear mission and commitment to develop a new class of plant-based health nutrition products that address unmet needs in the prevention and control of metabolic diseases. Worldwide, 39% of adults are overweight or obese1 , a major risk factor for premature death2 , often associated with metabolic disorders such as elevated fasting blood glucose, dyslipidemia or high blood pressure3 . Hundreds of millions of people around the world are affected. Valbiotis' pipeline and R&D platform represent a source of value for future alliances and a potential for rapid expansion, which will need to be supported by a commercial organization capable of targeting these significant markets, key to our priorities. As a member of the Strategic Direction Board and then of the Supervisory Board of Valbiotis since its creation, I have been able to follow the progress made in just a few years and to appreciate the strength of the strategy implemented, to which I intend to devote all my energy.’
About Valbiotis
Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, based on a multi-target approach enabled by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France: Périgny, La Rochelle (17) and Riom (63).
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit: www.valbiotis.com
.
1
World Health Organization, Global Health Observatory, www.who.int/data/gho/data/indicators/indicator-details/GHO/prevalence-of-overweight-among-adults-bmi-greaterequal-25-(crude-estimate)-(-)
(consulted on May 27, 2021).
2
World Health Organization, www.emro.who.int/fr/noncommunicable-diseases/causes/unhealthy-diets.html
(consulted on May 27, 2021).
3
The IDF consensus worldwide definition of the metabolic syndrome, International Diabetes Federation, 2006.
Name: Valbiotis
ISIN code: FR0013254851
Mnemonic code: ALVAL
EnterNext© PEA-PME 150
This press release contains forward-looking statements about Valbiotis' objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the Valbiotis registration document, approved by the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 20-018). This document is available on the Company's website (www.valbiotis.com
).
This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, Valbiotis' shares or securities in any country.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210607005510/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobix Labs Signs Definitive Agreement to Acquire Vision Aerial, Accelerating Global Drone Platform for National Security and Aerial Intelligence24.7.2026 13:00:00 CEST | Press release
Transaction accelerates Mobix Labs’ global aerial intelligence strategy and National Security Matters Initiative Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a definitive agreement to acquire Vision Aerial, Inc., a U.S.-based designer and manufacturer of American-built, National Defense Authorization Act (NDAA)-compliant unmanned aerial systems. The definitive agreement moves the transaction beyond the previously announced letter of intent and represents a major step toward closing an acquisition that would expand Mobix Labs into one of the world’s most important technology growth markets: secure drones, autonomous aerial systems and aerial intelligence for national security, critical infrastructure, energy, public safety, industrial inspection and government operations. Vision Aerial’s customers and end-users include the U.S. Air Force, U.S. Navy, government agencies, energy and utility operators, research institutions and other organizations requiring performanc
Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer24.7.2026 13:00:00 CEST | Press release
Recommendation based on DESTINY-Breast09 phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years If approved, Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab would become first new treatment in the EU in more than a decade for first-line HER2 positive metastatic breast cancer Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP)
SLB Announces Second-Quarter 2026 Results24.7.2026 12:50:00 CEST | Press release
Revenue of $8.97 billion increased 3% sequentially and 5% year on year GAAP EPS of $0.52 increased 4% sequentially and decreased 30% year on year EPS, excluding charges and credits, of $0.55 increased 6% sequentially and decreased 26% year on year Net income attributable to SLB of $786 million increased 5% sequentially and decreased 22% year on year Adjusted EBITDA of $1.90 billion increased 7% sequentially and decreased 7% year on year Cash flow from operations was $1.36 billion and free cash flow was $716 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the second-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722694386/en/ The exterior of the SLB headquarters in Houston, Texas.Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2026Mar. 31, 2026Jun. 30, 2025SequentialYear-on-yearRevenue $8,972 $8
NIQ Expands GenAI Capabilities Across gfknewron, Turning Trusted Intelligence into Decisions Faster24.7.2026 12:30:00 CEST | Press release
New capabilities help businesses uncover trends faster, simplify complex analysis, and accelerate confident decision-making NIQ (NYSE: NIQ), a leader in consumer intelligence, today announced the expansion of AI-powered Smart Insights across its gfknewron® platform. By bringing together markets and categories into a single view, gfknewron enables businesses to transform complex market, consumer and supply chain data into clear, actionable intelligence quickly. The latest enhancements help users identify trends, opportunities and performance drivers more quickly, reducing the time required to analyze large datasets and accelerating confident decision-making across teams. As brands and retailers face growing pressure to respond quickly to changing consumer behavior and market dynamics, the ability to unlock meaningful insights from increasingly rich datasets has become a significant competitive advantage. As AI is only as effective as the intelligence behind it, Smart Insights helps busi
Thales to Strengthen Romania’s Airspace Protection With Twelve Ground Master 200 MM/A Radars24.7.2026 10:05:00 CEST | Press release
The Romanian General Directorate for Armaments and the French Direction Générale de l’Armement (DGA – the French defence procurement agency) have signed an agreement to supply twelve Thales GM200 Multi-Mission All-in-one (GM200 MM/A) radars to protect the Romanian airspace. This government-to-government agreement underlines the high level of partnership between France and Romania, within the framework of the European Union’s SAFE funding programme, in order to bolster Europe’s defence capabilities. The GM200 MM/A is part of Thales’ proven Ground Master radar family, which has already been deployed in over 40 countries, including now in Romania. In a context of growing collaboration between European nations to bolster collective security, the Romanian General Directorate for Armaments has just signed a landmark agreement with France’s Direction Générale de l’Armement (DGA) to acquire twelve Thales Ground Master 200 Multi-Mission All-in-one (GM200 MM/A) radars. This government-to-governm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom